1Razi Pathobiology and Medical Genetic Laboratory, Karaj, Iran
2Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4Department of Biology, School of Biological Sciences, Sabzevar Branch, Islamic Azad University, Savzevar, Iran
5Department of Medical Genetics, School of Medicine, Tabriz University of Medical Science, Tabriz, Iran
چکیده
Pelizaeus-Merzbacher-Like Disease 1 is a genetic disorder affecting the central nervous system with an autosomal recessive inheritance pattern. It is a rare genetic disorder that affects the central nervous system. In this report, we demonstrated the clinical and paraclinical features of an Iranian consanguine pedigree with suspected hypomyelinating leukodystrophy, without any defined diagnosis. The proband, a 15-month-old girl, visited the Razi pathobiology and medical genetic laboratory of Karaj, where the study was conducted in 2020. Following whole-exome sequencing analysis of the proband and segregation analysis, a novel pathogenic mutation was discovered. GJC2 (NM_020435.4):c.1096dupG was found to be homozygous in the proband and heterozygous in both parents. This mutation was in the coding region of the protein, which results in D366Gfs*126 (p.Asp366GlyfsTer126). The site of mutation was at the 3’ region of the connexin superfamily domain. The frameshift results in a different peptide sequence of the C-terminal and extended protein. Our findings led to the diagnosis of the proband’s disease as Pelizaeus-Merzbacher-Like Disease 1 and led to the end of the diagnostic odyssey. We provided effective genetic counseling through the identification of a novel pathogenic mutation in gap junction protein C2 in this family and suggested preimplantation genetic diagnosis for the next pregnancy. Furthermore, our findings confirmed the association of GJC2 mutations with PMLD1. This discovery added to the repertoire of genetic mutations of Pelizaeus-Merzbacher-Like Disease 1. This knowledge could be applied for expanded carrier screening of other families, especially for Iranian consanguine marriages.
Ashrafi MR, Tavasoli AR. Childhood leukodystrophies: A literature review of updates on new definitions, classification, diagnostic approach and management. Brain Dev. 2017;39:369-85. doi: 10.1016/j.braindev.2017.01.001. PubMed PMID: 28117190.
Pouwels PJ, Vanderver A, Bernard G, Wolf NI, Dreha-Kulczewksi SF, Deoni SC, et al. Hypomyelinating leukodystrophies: translational research progress and prospects. Ann Neurol. 2014;76:5-19. doi: 10.1002/ana.24194. PubMed PMID: 24916848.
Nahhas N, Conant A, Orthmann-Murphy J, Vanderver A, Hobson G. Pelizaeus-Merzbacher-Like Disease 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al, editors. GeneReviews((R)). [updated 2019 Jan 17]. Seattle: University of Washington,1993-2021.
van der Knaap MS, Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134:351-82. doi: 10.1007/s00401-017-1739-1. PubMed PMID: 28638987; PubMed Central PMCID: PMCPMC5563342.
Charzewska A, Wierzba J, Izycka-Swieszewska E, Bekiesinska-Figatowska M, Jurek M, Gintowt A, et al. Hypomyelinating leukodystrophies - a molecular insight into the white matter pathology. Clin Genet. 2016;90:293-304. doi: 10.1111/cge.12811. PubMed PMID: 27234264.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24. doi: 10.1038/gim.2015.30. PubMed PMID: 25741868; PubMed Central PMCID: PMCPMC4544753.
Sanger F, Coulson AR. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol. 1975;94:441-8. doi: 10.1016/0022-2836(75)90213-2. PubMed PMID: 1100841.
Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74:5463-7. doi: 10.1073/pnas.74.12.5463. PubMed PMID: 271968; PubMed Central PMCID: PMCPMC431765.
Blum M, Chang HY, Chuguransky S, Grego T, Kandasaamy S, Mitchell A, et al. The InterPro protein families and domains database: 20 years on. Nucleic Acids Res. 2021;49:D344-D54. doi: 10.1093/nar/gkaa977. PubMed PMID: 33156333; PubMed Central PMCID: PMCPMC7778928.
Diekmann S, Henneke M, Burckhardt BC, Gartner J. Pelizaeus-Merzbacher-like disease is caused not only by a loss of connexin47 function but also by a hemichannel dysfunction. Eur J Hum Genet. 2010;18:985-92. doi: 10.1038/ejhg.2010.61. PubMed PMID: 20442743; PubMed Central PMCID: PMCPMC2987409.
Tress O, Maglione M, Zlomuzica A, May D, Dicke N, Degen J, et al. Pathologic and phenotypic alterations in a mouse expressing a connexin47 missense mutation that causes Pelizaeus-Merzbacher-like disease in humans. PLoS Genet. 2011;7:e1002146. doi: 10.1371/journal.pgen.1002146. PubMed PMID: 21750683; PubMed Central PMCID: PMCPMC3131295.
Moreno AP, Lau AF. Gap junction channel gating modulated through protein phosphorylation. Prog Biophys Mol Biol. 2007;94:107-19. doi: 10.1016/j.pbiomolbio.2007.03.004. PubMed PMID: 17507079; PubMed Central PMCID: PMCPMC1973155.
Omori Y, Mesnil M, Yamasaki H. Connexin 32 mutations from X-linked Charcot-Marie-Tooth disease patients: functional defects and dominant negative effects. Mol Biol Cell. 1996;7:907-16. doi: 10.1091/mbc.7.6.907. PubMed PMID: 8816997; PubMed Central PMCID: PMCPMC275942.
Castro C, Gomez-Hernandez JM, Silander K, Barrio LC. Altered formation of hemichannels and gap junction channels caused by C-terminal connexin-32 mutations. J Neurosci. 1999;19:3752-60. PubMed PMID: 10234007; PubMed Central PMCID: PMCPMC6782695.
